Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFMWLQ)

Drug Name

JS004 Drug Info

Synonyms

TAB004

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B- and T-lymphocyte attenuator (BTLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY3361237	DMHXMYU	Sjogren syndrome	4A43.20	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B- and T-lymphocyte attenuator (BTLA)	TTER58P	BTLA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04137900) Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Junshi Biosciences.
3	ClinicalTrials.gov (NCT05781451) A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome. U.S.National Institutes of Health.